Buy Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25) (Human, IgG1, kappa) for FCM, Neutralization

Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25)

Catalog #: RVV02809 Specific References (9) DATASHEET

Flow Cytometry for Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25) ?>

ELISA for Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25) ?>

Host species: Human

Isotype: IgG1, kappa

Applications: FCM, Neutralization

Expression system: Mammalian Cells

Overview

Catalog No.

RVV02809

Expression system

Mammalian Cells

Species reactivity

Human respiratory syncytial virus A (strain A2)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

FCM, Neutralization

Target

F, Fusion glycoprotein F0, Protein F, CR9515,RSV

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

D25

Note

For research use only.

Data Image

Bioactivity

Detects HRSV-A F protein in indirect ELISAs.
Bioactivity

Detects HRSV-A2 Pre-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV Post-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.
Flow Cytometry

The percentage of cells transfected with the rAAV5-RSV-F and rAAV5-RSV-Fm vaccines that expressed membrane-associated forms of the RSV F protein bound by D25, 4D7, or AM14 was determined (A, B). (n=3) Statistical significance was calculated via two-way ANOVA with Dunnett's multiple comparisons. P values were adjusted for multiple comparisons. **p < 0.01, ***p < 0.001.
Data sourced from citation (PMID: 39469716)
Bioactivity

BLI profiles of BR38 (A), BR40 (B), and BR42 (C). Each column depicts interactions with Nirsevimab, D25, AM14-1, AM14-2, MPE8, and Palivizumab from top to bottom.
Data sourced from citation (PMID: 39874917)
Flow Cytometry

(D) Staining of WT RSV-A-infected HEp2 cells and S190R RSV-A-infected HEp2 cells with a panel of monoclonal antibodies. The x-axis depicts the monoclonal antibodies that were used for staining. The y-axis depicts the mean fluorescent index (MFI) that was recorded with each antibody. The columns are colour-coded based on the RSV F antigenic site that is targeted by the antibody. The figure shows a summary of three independent experiments, each depicted by a dot with standard errors. Statistically significant differences are shown (***P < .005, ****P < .001, ns, nonsignificant, Student's t-test).
Data sourced from citation (PMID: 41660179)
Bioactivity

The table presents affinity coefficients of BR38, BR40, and BR42 with various mAbs. BR40 shows superior antigenicity, while BR42 demonstrates comparable performance. BR38 exhibits inferior characteristics, notably decreased affinity to AM14.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)
ELISA

Figure S1. Antigenic characteristics and stability of different antigens. The binding activities of serial diluted antigens to site Ø antibody D25 (A), and site Ⅰ antibody 4D7 (B)
Data sourced from citation (PMID: 42085934)

References

Evaluate of the protective effect of an RSV Pre-F/Alum +CpG subunit vaccine in Balb/C mice with and without RSV prexposure. [RVV02809]

The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity. [RVV02809]

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization., PMID:2251875

Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage., PMID:1375280

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic., PMID:11277694

Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection., PMID:29029312

Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response., PMID:33574352

Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine. [RVV02809]

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice. [RVV02809]

Datasheet

Document Download

Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25).pdf

$ 372

Product specifications

100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here